• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.

作者信息

Clark C Amos, Mosse Claudio A, Chen Heidi, Byrne Michael, Chinratanalab Wichai, Engelhardt Brian G, Goodman Stacey A, Harrell Shelton L, Kassim Adetola A, Savani Bipin N, Sengsayadeth Salyka, Jagasia Madan, Cornell R Frank

机构信息

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Department of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

出版信息

Bone Marrow Transplant. 2018 Dec;53(12):1589-1592. doi: 10.1038/s41409-018-0241-2. Epub 2018 Jun 18.

DOI:10.1038/s41409-018-0241-2
PMID:29915217
Abstract
摘要

相似文献

1
Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy.硼替佐米为主的化疗时代，多参数流式细胞术评估多发性骨髓瘤微小残留病的前瞻性试验
Bone Marrow Transplant. 2018 Dec;53(12):1589-1592. doi: 10.1038/s41409-018-0241-2. Epub 2018 Jun 18.
2
Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.多发性骨髓瘤特刊引言：微小残留病的流式细胞术检测
Cytometry B Clin Cytom. 2016 Jan;90(1):9-10. doi: 10.1002/cyto.b.21342.
3
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20.
4
The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study.硼替佐米的引入对肾功能损害的多发性骨髓瘤患者透析独立性的影响：一项基于荷兰全国人口的研究。
Haematologica. 2018 Jul;103(7):e311-e314. doi: 10.3324/haematol.2017.184754. Epub 2018 Mar 15.
5
XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach.XPO1 是多发性骨髓瘤硼替佐米耐药的关键因素：一种定量蛋白质组学方法。
J Proteomics. 2019 Oct 30;209:103504. doi: 10.1016/j.jprot.2019.103504. Epub 2019 Aug 26.
6
Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.硼替佐米通过调节 HSP27 促进多发性骨髓瘤细胞凋亡。
Mol Med Rep. 2019 Sep;20(3):2410-2418. doi: 10.3892/mmr.2019.10467. Epub 2019 Jul 3.
7
Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.异质性12号染色体短臂缺失是多发性骨髓瘤独立的不良预后因素，且对基于硼替佐米的治疗耐药。
Oncotarget. 2015 Apr 20;6(11):9434-44. doi: 10.18632/oncotarget.3319.
8
Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.透明质酸壳和二硫键交联核胶束用于体内靶向递送硼替佐米治疗多发性骨髓瘤。
Acta Biomater. 2018 Oct 15;80:288-295. doi: 10.1016/j.actbio.2018.09.022. Epub 2018 Sep 19.
9
Bortezomib improves survival in rare myeloma.硼替佐米可提高罕见骨髓瘤患者的生存率。
Lancet Oncol. 2016 Jun;17(6):e227. doi: 10.1016/S1470-2045(16)30129-2. Epub 2016 May 6.
10
Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.通过流式细胞术和质谱细胞术对硼替佐米耐药性多发性骨髓瘤细胞系进行表型和功能特征分析
Leuk Lymphoma. 2017 Aug;58(8):1931-1940. doi: 10.1080/10428194.2016.1266621. Epub 2016 Dec 16.

引用本文的文献

1
Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.基于证据的韩国多发性骨髓瘤临床管理指南：解决12个关键临床问题。
Blood Res. 2025 Feb 4;60(1):9. doi: 10.1007/s44313-025-00055-9.
2
Minimal Residual Disease in Multiple Myeloma: Something Old, Something New.多发性骨髓瘤中的微小残留病：旧貌新颜。
Cancers (Basel). 2021 Aug 27;13(17):4332. doi: 10.3390/cancers13174332.
3
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
一项大型荟萃分析确立了 MRD 阴性在多发性骨髓瘤患者长期生存结局中的作用。
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.